MindWalk Holdings Corp. (NASDAQ: HYFT) announced the launch of its Pandemic Response Platform, designed for outbreak preparedness and countermeasure development against RNA viruses. The platform utilizes the company's HYFT biological pattern system and LensAI platform.

The announcement comes as two World Health Organization-declared emergencies highlight gaps in current vaccine coverage. The Bundibugyo Ebola outbreak illustrates this challenge, as the only approved Ebola vaccine was developed for the Zaire strain, leaving no approved vaccine for the structurally distinct Bundibugyo species.

The platform targets structural constraints that RNA viruses must preserve across variants, rather than focusing on surface proteins that mutate rapidly. According to the company, this approach aims to maintain effectiveness as viruses evolve.

MindWalk's system draws on what it describes as 660 million biological patterns and 25 billion relationships accumulated over 20 years. The platform is currently deployed on the company's pan-serotype Dengue and universal Influenza programs, both at in vivo proof-of-concept stage with cross-strain neutralization assays underway.

"Every outbreak response organized around the surface of a pathogen is a race the pathogen is built to win," said Dr. Jennifer Bath, CEO and President of MindWalk Holdings. "We built the Pandemic Response Platform because we believed the only durable answer was to target the architecture the virus cannot change."

The World Health Organization tracks more than 1,650 epidemic events globally per year. The Coalition for Epidemic Preparedness Innovations established a benchmark of delivering safe and effective vaccines within 100 days of a pathogen sequence becoming available.

MindWalk states that more than 20 molecules from its programs have advanced to clinical trials. The company operates antibody discovery sites in Victoria, British Columbia and Fargo, North Dakota.